Study guide
1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation
ARRT Radiation Therapy Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient Care & Education
1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation
2 Chapter 2: Radiation Physics, Radiobiology & Protection
2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients
3 Chapter 5: Treatment Sites, Tumors & Classification
5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems
4 Chapter 3: Treatment Planning & Dosimetry
3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances
5 Chapter 4: Treatment Delivery, Image Guidance & QA
4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation
1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation
Key Takeaways Explain This Topic AI
Cancer risk factors include tobacco, alcohol, UV exposure, oncogenic viruses, inherited syndromes, and occupational exposures relevant to site-specific disease.
Screening aims to detect disease before symptoms; diagnostic tests evaluate symptoms or abnormal screening findings.
Therapist chart review should connect screening and diagnostic history (imaging, labs, pathology, operative reports) to the intended treatment site and stage.
Incidence and prevalence concepts explain clinic case mix; evaluation literacy supports safe simulation and delivery decisions.
Last updated: July 2026
Why Evaluation Content Appears on the ARRT Exam
Under Patient Care → Patient and Medical Record Management → Evaluation , ARRT expects entry-level therapists to understand epidemiology and etiology concepts, cancer screening, signs and symptoms, history and physical findings, and how imaging, laboratory, surgical, and pathology data feed the treatment record. This is not a public-health elective. It is the clinical context for reading a chart before simulation and treatment delivery.
Therapists rarely assign formal stage or order screening tests, but they must recognize why a patient arrived with a given diagnosis, which comorbidities travel with high-risk exposures, and which documents confirm site, laterality, and intent before immobilization.
- Epidemiology and Etiology Basics
- Incidence: new cases in a defined population over a defined time period
- Prevalence: existing cases at a point in time or during a period
- Risk factors: exposures or traits that raise the probability of developing cancer
- Factor category Examples linked to common RT sites
- Tobacco Lung, head and neck, bladder, esophagus
- Alcohol (with tobacco synergy) Oral cavity, pharynx, esophagus, larynx
- Ultraviolet / ionizing radiation Skin cancers; secondary malignancy risk context
- Oncogenic viruses HPV (oropharynx, cervix), HBV/HCV (liver), EBV (some lymphomas/nasopharynx)
- Hormonal / reproductive Breast, endometrium
- Inherited syndromes BRCA-related breast/ovarian; Lynch (colorectal/endometrial)
- Occupational / environmental Asbestos (mesothelioma/lung), benzene (leukemia risk context)
Therapists do not diagnose etiology, but recognizing risk-factor patterns supports patient education and explains why certain toxicities and comorbidities cluster. Heavy smokers often present with COPD and limited breath-hold capacity. Patients with alcohol-associated head-and-neck disease frequently need early nutrition and airway awareness. Hepatobiliary cases may carry cirrhosis-related lab abnormalities that affect contrast CT simulation decisions.
Prevalence vs incidence in clinic language
High incidence cancers (breast, prostate, lung, colorectal) dominate daily linac schedules. A disease can have moderate incidence yet high prevalence when survival is long, which is why survivors and re-irradiation consults appear in chart queues. Exam items may ask you to distinguish new-case rates from existing-case burden without requiring memorization of national registry percentages.
Cancer Screening vs Diagnostic Workup
Screening tests asymptomatic people at elevated risk to find disease earlier. Diagnostic tests evaluate signs, symptoms, or abnormal screening results.
- Site / population Common screening approach (high-level)
- Breast Mammography according to age and risk guidelines
- Cervix Pap testing and/or HPV testing
- Colorectal Colonoscopy or stool-based screening programs
- Lung (high-risk smokers) Low-dose CT screening programs
- Prostate PSA with shared decision-making rather than a universal mandate
After a positive screen or symptomatic presentation, staging workup may include CT, MRI, PET/CT, endoscopy, biopsy, and labs (CBC, metabolic panel, tumor markers such as PSA). The radiation therapist reviews these reports to confirm site, laterality, and clinical context before immobilization and beam delivery.
Screening pitfalls therapists should recognize
An incidental PET-avid finding is not the same as a completed staging package.
Screening modality does not equal treatment modality: low-dose CT screening is diagnostic imaging, not therapeutic radiation.
Negative screening history does not rule out cancer; many radiation patients present with symptoms after never participating in organized screening.
Shared decision-making language around PSA means the chart may show declining screening rather than a missed diagnosis.
Signs, Symptoms, and History Clues
Chart review should flag:
- Chief complaint and duration (hemoptysis, dysphagia, rectal bleeding, bone pain, neurologic deficit)
- Prior surgery, chemotherapy, immunotherapy, or hormone therapy
- Prior radiation (re-irradiation and cumulative dose concerns)
- Performance status and comorbidities affecting setup tolerance
- Allergies, anticoagulation, implantable devices, and infection-control status
- Pathology and staging linkage
Pathology reports establish histopathologic type (carcinoma versus sarcoma versus hematologic disease) and grade. Staging systems such as TNM and Ann Arbor (lymphoma) organize anatomic extent. Therapists do not assign formal stage, but must recognize that prescription intent (definitive, adjuvant, or palliative) and field design follow stage and histology documented in the record.
When pathology and imaging disagree on extent, stop and escalate rather than inventing a compromise target. The evaluation package exists so simulation and delivery mirror the oncologist’s documented disease description.
Imaging Studies and Other Diagnostics in the Evaluation Bundle
- Study Typical radiation oncology use
- CT Staging and CT simulation baseline anatomy
- MRI Soft-tissue, brain, spine, and pelvis detail; fusion for contouring
- PET/CT Metabolic extent support for lymphoma, lung, and head-and-neck staging
- Labs CBC for marrow tolerance; creatinine/eGFR for contrast CT sim; PSA trends
- Operative notes Surgical margins, residual disease, reconstructive hardware affecting setup
- Pathology Histology, grade, biomarkers that may change concurrent therapy expectations
- Connecting evaluation data to daily therapist decisions
Oxygen dependence and dyspnea from lung disease change immobilization and timing of imaging.
Pain from bone metastases may require premedication before lengthy simulation.
Prior neck dissection or reconstructive flaps change surface landmarks and mask fit.
Rising PSA after prostatectomy changes salvage-versus-palliative framing even when the therapist does not interpret the lab alone.
Clinical Scenarios
Scenario A — screen-detected lung cancer. A 55-year-old with a 40-pack-year history has an LDCT-detected nodule, PET-avid mediastinal nodes, and biopsy-proven adenocarcinoma. Before CT simulation, expect thoracic immobilization needs, possible respiratory motion management discussion, and review of nodal stations referenced in notes. Do not treat the case as an incidental soft-tissue mass without epidemiologic context.
Scenario B — symptomatic colorectal presentation. A patient with rectal bleeding skipped colonoscopy screening for a decade. Staging MRI and endoscopy describe a low rectal primary. Simulation planning must account for full-bladder or empty-rectum instructions documented in the education plan, and the therapist should anticipate skin and bowel side-effect teaching tied to pelvic fields.
Scenario C — inherited-risk breast case. A young patient with a BRCA-associated diagnosis may have bilateral surgical history or reconstruction hardware. Evaluation notes about laterality, expanders, and prior radiation are mandatory verification items before any tangent or regional-nodal setup.
Connecting Evaluation Data to the Treatment Record
ARRT expects therapists to recognize what belongs in evaluation documentation:
- Epidemiology and etiology clues in the history of present illness
- Screening pathway that discovered disease (program-based versus incidental versus symptomatic)
- Signs and symptoms prompting diagnostic imaging
History and physical findings affecting setup (pain, oxygen dependence, limited abduction, neurologic deficits)
- Imaging studies (CT/MRI/PET) and other diagnostics (labs, operative notes, pathology)
- Worked chart-review pattern
Identify primary site and histology from pathology.
Note stage language (TNM or Ann Arbor) and intent (definitive, adjuvant, palliative).
List prior therapies that change tolerance (chemotherapy, surgery, prior radiation).
Flag labs that gate procedures (CBC before marrow-toxic concurrent chemoradiation; creatinine/eGFR before contrast CT simulation).
Confirm laterality and site match consent, prescription, and setup notes.
Capture screening-versus-diagnostic pathway in plain language so education stays accurate.
Incidence Patterns Therapists Actually See
High-volume clinics commonly treat breast, prostate, lung, and colorectal cancers because population incidence is high. Less common diagnoses (sarcomas, some pediatric tumors, rare head-and-neck subsites) still appear and require careful site-specific immobilization knowledge. Understanding incidence does not replace site anatomy study, but it explains why certain side-effect pathways and emergency presentations such as superior vena cava syndrome or cord compression recur in teaching cases.
Keep evaluation literacy practical: the exam rewards connecting risk history, screening pathway, and diagnostic documents to safe simulation and delivery decisions, not memorizing registry tables.